Infect Chemother.
2022 Sep;54(3):547-548. 10.3947/ic.2022.0039.
Regdanvimab Treatment of COVID-19
- Mungmunpuntipantip R
1 - Wiwanitkit V2,3,4,5
- Affiliations
-
- 1Private Academic Consultant, Bangkok, Thailand
- 2Joseph Ayobaalola University, Ikeji-Arakeji, Nigeria
- 3Dr DY Patil University, Pune, India
- 4Faculty of Medicine, University of Nis, Serbia
- 5Parasitic Disease Research Center, Suranaree University of Technology, Nakhon Ratchasima, Thailand
- KMID: 2534168
- DOI: http://doi.org/10.3947/ic.2022.0039
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Real World Experience with Regdanvimab Treatment of Mild-toModerate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea
- Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance
- Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis
- Effectiveness of Regdanvimab and Remdesivir in Patients with COVID-19 at a Single Hospital
- Effectiveness and Safety of Regdanvimab in Patients With Mild-ToModerate COVID-19: A Retrospective Cohort Study
